Record Q1 growth masks margin compression ahead

Revenue 8,277 Cr, EBITDA 2,464 Cr—both exceeded stated marks

India 13.9%, Other Developed 48%, Emerging 52%—aggregate ~20%+ excluding US's 43% YoY

Q1 USD 366M; guidance implies USD 250–280M per quarter Q2–Q4, citing Tolvaptan/Mirabegron competition

Revenue +32% YoY but PAT +16% YoY; NPM 16.9% vs 17.6% prior year—margin compression underway

Q1 exceptional at 74.6%, but management cites old inventory and warns normalization due to Tolvaptan pricing pressure and input cost inflation

FY27 'high single-digit growth' reiterated; EBITDA 25% reaffirmed despite Q1's 32% revenue growth and 29.6% margin—management transparently explains Q1 as non-repeatable

Prior call noted 'increased competition' in Tolvaptan/Mirabegron; now explicitly guided USD 250–280M quarterly run rate Q2–Q4 vs USD 366M in Q1 (25% QoQ drop)

Geopolitical tensions causing input cost rises; first quarter insulated by old inventory, but H2 FY27 will see margin pressure

50+ launches over 3 years (vs prior guidance on 'complex products'); Spiriva Respimat filing this year; Apixaban 505(b)(2) September approval target confirmed

Tolvaptan had no competition in Q1; from Q2, Apotex and Teva enter, potentially 3rd player in Sep. Mirabegron pressure started Q1, full impact from Q2. Four-player market expected; pricing/share reallocation will occur. Full justification given.

Function of Tolvaptan realization, competitive dynamics, and geopolitical cost inflation. Q1 not hugely impacted due to old inventory; going forward, cost increases must flow through. Being 'a little more cautious' on 24–25% EBITDA range.

Yes. Market share tail will be longer due to specialty pharmacy + REMS program, but we will give share to entrants. Expect to sustain position but cede some share.

Still sizing up but targeting channels strategically via national accounts. It could potentially get there. Very large brand, so opportunity is material.

Material opportunity. Over 3 years: couple of hundred million dollars scale business across US and Europe. Pegfilgrastim U.S., Ranibizumab Europe (big opportunity, leveraging VISUfarma footprint), Aflibercept FY29, Etanercept FY30.

Albuterol stabilized at 16%; no imminent competitive launches on Tiotropium. Baseline should stay stable as Dulera, nasal sprays, and Respimat come to market over next year.

Dynamic. On one side, rebates up on part of portfolio; on other, biosimilars (Ranibizumab, Aflibercept) no longer in AOK tenders—now branded opportunities. Europe struggling with drug spend budgets but incentivizing biosimilars; Lupin well-positioned with portfolio.

Three avenues: internal pipeline, in-licensing, pure innovative NCEs (e.g., Bofanglutide in clinical development). 10–15 products per year target. Respiratory, cardiology, diabetes focus; 50% of assets in oncology where Lupin weak. Model looks good; similar or better profitability expected.

Definitely an unmet need for patients we've targeted, but we'll come back closer to launch date. [Deferred full disclosure.]

Overall about 1–1.5% EBITDA margin impact. Expected to turn breakeven (Diagnostics) or profitable (Digital, OTC, CDMO) over coming quarters.

Conservative despite Q1's 32% YoY; moderation expected from Q2 due to Tolvaptan/Mirabegron competition. US business specifically guided to USD 1.1–1.2B (vs Q1's USD 366M annualized ~1.47B).

Q1's 29.6% described as exceptional (old inventory, no Tolvaptan competition). Normalization to 25% explicitly attributed to competitive intensity, input cost inflation (geopolitical), and adjacency losses (1–1.5%).

Q1 at 7.4%; full year expected 8%. Supporting complex and specialty platforms (respiratory, injectables, biosimilars, 505(b)(2) pipeline).

Tolvaptan and Mirabegron facing new generic entrants Q2 onwards. Management explicitly guides Q2–Q4 US revenue to USD 250–280M quarterly vs USD 366M in Q1. Pricing erosion and share loss expected.

EBITDA margin expected to compress 460 bps from Q1's 29.6% to ~25% FY27. Driven by Tolvaptan pricing erosion, input cost inflation (geopolitical), and adjacency losses (1–1.5% EBITDA). Could dip below 20% in a quarter.

50+ product launches over 3 years with 10 exclusive FTF, 5 biosimilars. Apixaban 505(b)(2) (September approval target), Pegfilgrastim (H2 FY27), Spiriva Respimat (P4 device challenge cleared, filing FY27), Fluticasone nasal spray (Rx approval FY27, OTC FY28). Any slippage delays US recovery from FY28.

India grew 13.9% YoY (prescription +15.1% vs IPM +13.5%). Chronic segment 67% (target 70%). Diabetes segment +31.8% (second quarter 20%+ growth). Sustainability risk if category growth moderates or pricing pressure mounts.

Germany doubled rebate requirements on part of portfolio. European healthcare budgets constrained. However, biosimilars (Ranibizumab, Aflibercept) excluded from tenders, becoming branded opportunities. VISUfarma acquisition provides ophthalmology footprint.